Last reviewed · How we verify
NCT05944198
Clinical Study of 18F-FAPI-RGD PET/CT in Rheumatoid Arthritis
trial in Rheumatoid Arthritis in 40 participants. Completed in 20 February 2024.
20 February 2024
Quick facts
| Lead sponsor | Sichuan Provincial People's Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 14 July 2023 |
| Primary completion | 20 February 2024 |
| Estimated completion | 20 February 2024 |
| Sites | 1 location across China |
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Sichuan Provincial People's Hospital
Who can join
Eligibility, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about 18F-FAPI-RGD PET/CT imaging in assessing rheumatoid arthritis disease activity. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dual targeting heterodimer PET tracer [<sup>18</sup>F]AlF‑FAPI‑RGD in patients with rheumatoid arthritis: a pilot exploratory study.
Wang H, Su W, He L, Wu D, et al · · 2024 · cited 5× · PMID 39629127 · DOI 10.7150/thno.102627
Verify or expand the search:
- PubMed search for NCT05944198
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Sichuan Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07298525 — Safety Exploration and Evaluation of Dexmedetomidine Hydrochloride Nasal Spray for Pre-anesthesia Sedation in Low-Monito · Phase 4 · not yet recruiting
- NCT07175363 — Butorphanol for Pain Relief After Cesarean Section: A Retrospective Study · not yet recruiting
- NCT07106996 — Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycysti · EARLY_PHASE1 · recruiting
- NCT07082946 — Mechanisms of Perioperative Systemic Inflammation in the Development of PND in Cirrhotic Patients · not yet recruiting
- NCT06821633 — Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05944198 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Provincial People's Hospital
- Last refreshed: 15 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05944198.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing